CIK 0001863127
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Tyra Biosciences, Inc.
Sign in to watch- Ticker
- TYRA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831476348
- Phone
- +1 619-728-4760
- Business address
- 2656 STATE STREET, CARLSBAD, CA, 92008
- Open-market buys, last 90 days
- $20,000
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$20,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-15 | Swanson Ronald V. Chief Scientific Officer | Grant or award | +3,125 | $8.53 | $27K | 273,254 |
| 2022-03-15 | Patel Piyush R. Chief Development Officer | Grant or award | +2,408 | $8.53 | $21K | 137,472 |
| 2022-03-15 | Hudkins Robert L. Chief Technology Officer | Grant or award | +2,408 | $8.53 | $21K | 272,536 |
| 2022-03-15 | Harris Todd Chief Executive Officer | Grant or award | +3,125 | $8.53 | $27K | 1,699,468 |
| 2021-12-17 | Boxer Capital, LLC 10% owner | Purchase | +125,000 | $13.12 | $1.6M | 6,448,359 |
| 2021-11-02 | van den Boom Esther Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +83,626 | 83,626 | ||
| 2021-11-02 | van den Boom Esther Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +7,964 | 7,964 | ||
| 2021-11-02 | van den Boom Esther Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +7,964 | 7,964 | ||
| 2021-11-02 | Patel Piyush R. Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +83,626 | 83,626 | ||
| 2021-11-02 | Patel Piyush R. Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +7,964 | 7,964 | ||
| 2021-11-02 | Patel Piyush R. Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +7,964 | 7,964 | ||
| 2021-11-02 | Tada Hiroomi Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +83,626 | 83,626 | ||
| 2021-11-02 | Tada Hiroomi Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +7,964 | 7,964 | ||
| 2021-11-02 | Tada Hiroomi Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +7,964 | 7,964 | ||
| 2021-11-02 | Hudkins Robert L. Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +83,626 | 83,626 | ||
| 2021-11-02 | Hudkins Robert L. Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +7,964 | 7,964 | ||
| 2021-11-02 | Hudkins Robert L. Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +7,964 | 7,964 | ||
| 2021-11-02 | Swanson Ronald V. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +83,626 | 83,626 | ||
| 2021-11-02 | Swanson Ronald V. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +7,964 | 7,964 | ||
| 2021-11-02 | Swanson Ronald V. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +7,964 | 7,964 |
Page 18 of 21 · 417 trades